Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór pęcherza moczowego wysokiego ryzyka bez wcześniejszego leczenia BCG (grupa A) lub z poprzednim leczeniem BCG (grupy B i CX)
- •Wszystkie widoczne ogniska nowotworu muszą być usunięte chirurgicznie w ciągu 90 dni przed rozpoczęciem leczenia
- •Prawidłowe funkcjonowanie narządów wewnętrznych na początku badania
- •Nowotwór wykryty i potwierdzony w ciągu 90 dni przed włączeniem do badania
✗ Disqualifies
- •Obecny lub przeszły rak pęcherza moczowego, który wnika w głębokie warstwy mięśniowe
- •Rozległy rak pęcherza z przerzutami do innych narządów
- •Nowotwór wysokiego stopnia zaawansowania w górnych drogach moczowych
- •Osłabiona odporność lub znaczące problemy z układem immunologicznym
- •Ciąża lub karmienie piersią
- •Dla grupy CX: poprzednie leczenie gemcytabiną w ciągu ostatnich 24 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (80)
Banner MD Anderson Cancer Center
Gilbert, United States
Mayo Clinic Arizona
Phoenix, United States
Arizona Urology Specialty
Tucson, United States
University of Arkansas for Medical Sciences
Little Rock, United States
Arkansas Urology
Little Rock, United States
Michael G Oefelein, MD Clinical Trials
Bakersfield, United States
City of Hope
Irvine, United States
Genesis Research (Greater Los Angeles)
Los Alamitos, United States
Advanced Urology
Los Angeles, United States
Urology Center of Southern California
Murrieta, United States
University of California, Irvine
Orange, United States
UC Davis
Sacramento, United States
Om research
San Diego, United States
University of Southern California
San Diego, United States
Genesis Research (Greater Los Angeles)
Torrance, United States
Colorado Urology
Lakewood, United States
Urology Associates, Lone Tree
Lone Tree, United States
University of Florida
Gainesville, United States
Mayo Clinic Florida
Jacksonville, United States
Advanced Urology Institute (Solaris)
Largo, United States
Advanced Urology Institute
Oxford, United States
Advanced Urology Institute - Tallahassee (Solaris)
Tallahassee, United States
Emory University
Atlanta, United States
Associated Urological Specialists
Chicago Ridge, United States
Uropartners
Glenview, United States
Accellacare
Lisle, United States
Urology of Indiana - Carmel
Carmel, United States
Urology of Indiana, LLC (US Urology Partners)
Greenwood, United States
First Urology, PSC
Jeffersonville, United States
Urologic Specialists of Northwest Indiana (Solaris)
Merrillville, United States
Urology Center of Iowa Research
Clive, United States
Wichita Urology Group
Wichita, United States
Southern Urology (Urology America)
Lafayette, United States
Ochsner Medical Center
New Orleans, United States
Anne Arundel Urology
Annapolis, United States
Chesapeake Urology Research Associates
Hanover, United States
Brigham and Women's Hospital
Boston, United States
Comprehensive Urology
Royal Oak, United States
Michigan Institute of Urology (Solaris)
Troy, United States
Mayo Clinic Rochester
Rochester, United States
Minnesota Urology
Woodbury, United States
Specialty Clinical Research of St. Louis
St Louis, United States
Adult and Adolescent Urology
Omaha, United States
Hackensack University Medical Center
Hackensack, United States
Integrated Medical Professionals, PLLC (Solaris)
New York, United States
University of Rochester
Rochester, United States
SUNY Upstate
Syracuse, United States
Associated Medical Professionals of NY, PLLC (US Urology Partners)
Syracuse, United States
Montefiore Medical Center
The Bronx, United States
University of North Carolina
Chapel Hill, United States
Atrium Health/Levine Center
Charlotte, United States
Associated Urologist of North Carolina (Solaris)
Raleigh, United States
The Urology Group (Solaris)
Cincinnati, United States
University of Cincinnati Cancer Center
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
Ohio State University
Columbus, United States
Central Ohio Urology Group (US Urology Partners)
Gahanna, United States
Oregon Health & Science University
Portland, United States
Portland VA
Portland, United States
Oregon Urology Institute
Springfield, United States
Midlantic Urology (Solaris)
Bala-Cynwyd, United States
Penn State University Milton S. Hershey Medical Center
Hershey, United States
Keystone Urology Specialists
Lancaster, United States
University of Pennsylvania
Philadelphia, United States
Charleston Area Medical Center
Charleston, United States
Carolina Urologic Research Center, LLC
Myrtle Beach, United States
Lowcountry Urology (Solaris)
North Charleston, United States
The Conrad Pearson Clinic (Urology America)
Germantown, United States
Urology Associates, PC
Nashville, United States
Amarillo Urology Research
Amarillo, United States
UPNT Research Institute, LLC
Arlington, United States
Urology Austin, PLLC (Urology America)
Austin, United States
Urology Clinics of North Texas, PLLC
Dallas, United States
UT Southwestern Medical Center
Dallas, United States
Houston Methodist
Houston, United States
Urology San Antonio, PA dba USA Clinical Trials
San Antonio, United States
Potomac Urology
Alexandria, United States
Urology of Virginia
Virginia Beach, United States
Spokane Urology
Spokane, United States
Centre of Applied Urology Research Nova Scotia Health Authority
Halifax, Canada
Trial contact
Rebecca Tregunna, MD
Pat Keegan, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.